{"id":10272,"date":"2026-07-15T11:57:06","date_gmt":"2026-07-15T09:57:06","guid":{"rendered":"https:\/\/cleanpeptides.eu\/cagrilintide-guia-dosagem\/"},"modified":"2026-07-15T11:57:06","modified_gmt":"2026-07-15T09:57:06","slug":"cagrilintide-guia-dosagem","status":"publish","type":"page","link":"https:\/\/cleanpeptides.eu\/pt-pt\/cagrilintide-guia-dosagem\/","title":{"rendered":"Guia de dosagem Cagrilintida"},"content":{"rendered":"<p><em>Apenas para fins de investiga\u00e7\u00e3o \u2014 n\u00e3o destinado ao uso humano. A Clean Peptides n\u00e3o fornece aconselhamento sobre dosagem ou utiliza\u00e7\u00e3o. Este guia re\u00fane informa\u00e7\u00e3o do produto e material educativo independente como refer\u00eancia de investiga\u00e7\u00e3o; n\u00e3o constitui aconselhamento m\u00e9dico.<\/em><\/p>\n<p><strong>Aviso \u2014 medicamento experimental:<\/strong> a Cagrilintida (AM833) N\u00c3O est\u00e1 aprovada pela FDA. As doses aqui indicadas prov\u00eam de ensaios cl\u00ednicos publicados, n\u00e3o de um folheto aprovado.<\/p>\n<h2>O que \u00e9 a Cagrilintida?<\/h2>\n<p>A Cagrilintida (AM833) \u00e9 um an\u00e1logo da amilina de a\u00e7\u00e3o prolongada desenvolvido pela Novo Nordisk. A amilina \u00e9 uma hormona natural libertada com a insulina ap\u00f3s as refei\u00e7\u00f5es que sinaliza saciedade; a cagrilintida copia esse sinal numa forma que dura cerca de uma semana, de modo que uma \u00fanica inje\u00e7\u00e3o semanal mant\u00e9m o apetite reduzido. \u00c9 estudada isoladamente e combinada com semaglutida numa \u00fanica inje\u00e7\u00e3o semanal chamada CagriSema. No ensaio de fase 3 REDEFINE 1, o CagriSema produziu uma perda de peso de 20,4 % \u00e0s 68 semanas.<\/p>\n<h2>Caracter\u00edsticas principais<\/h2>\n<ul>\n<li>An\u00e1logo da amilina de a\u00e7\u00e3o prolongada \u2014 copia a hormona da saciedade p\u00f3s-refei\u00e7\u00e3o; dura ~uma semana.<\/li>\n<li>Apetite e saciedade \u2014 atua sobre as regi\u00f5es cerebrais do controlo da fome.<\/li>\n<li>Esvaziamento g\u00e1strico mais lento \u2014 prolonga a saciedade.<\/li>\n<li>Combina\u00e7\u00e3o CagriSema \u2014 associada \u00e0 semaglutida 2,4 mg numa inje\u00e7\u00e3o semanal.<\/li>\n<li>Inje\u00e7\u00e3o semanal \u2014 semivida ~7\u20138 dias.<\/li>\n<li>Experimental \u2014 CagriSema em an\u00e1lise pela FDA.<\/li>\n<\/ul>\n<h2>Como se determina a dose<\/h2>\n<p>Prov\u00e9m diretamente de ensaios controlados. Fase 2 em monoterapia (Lau et al., Lancet 2021, n=706): perda de peso dependente da dose.<\/p>\n<figure class=\"wp-block-table\">\n<table style=\"border-collapse:collapse;width:100%\">\n<tr>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Grupo (semanal)<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Perda de peso m\u00e9dia<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Placebo<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">3,0 %<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Cagrilintida 0,3\u20132,4 mg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">6,0 % a 9,7 %<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Cagrilintida 4,5 mg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">10,8 %<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Liraglutida 3,0 mg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">9,0 %<\/td>\n<\/tr>\n<\/table>\n<\/figure>\n<figure class=\"wp-block-table\">\n<table style=\"border-collapse:collapse;width:100%\">\n<tr>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Ensaio<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Popula\u00e7\u00e3o<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">CagriSema<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Placebo<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">REDEFINE 1<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Sem diabetes<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">20,4 %<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">3,0 %<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">REDEFINE 2<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Diabetes tipo 2<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">13,7 %<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">3,4 %<\/td>\n<\/tr>\n<\/table>\n<\/figure>\n<h2>Protocolos de dosagem<\/h2>\n<p><strong>Cagrilintida isolada:<\/strong><\/p>\n<figure class=\"wp-block-table\">\n<table style=\"border-collapse:collapse;width:100%\">\n<tr>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Per\u00edodo<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Dose semanal<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Objetivo<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Passo 1<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">0,3 mg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Toler\u00e2ncia inicial, aclimata\u00e7\u00e3o g\u00e1strica<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Passo 2<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">0,6 mg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Primeiro aumento<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Passo 3<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">1,2 mg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Aproximando-se do intervalo terap\u00eautico<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Manuten\u00e7\u00e3o<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">2,4 mg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Alvo estabelecido (at\u00e9 4,5 mg estudado)<\/td>\n<\/tr>\n<\/table>\n<\/figure>\n<p><strong>CagriSema (cada componente):<\/strong><\/p>\n<figure class=\"wp-block-table\">\n<table style=\"border-collapse:collapse;width:100%\">\n<tr>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Per\u00edodo<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Cada componente (semanal)<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Dura\u00e7\u00e3o<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Passo 1<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">0,25 mg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Semanas 1\u20134<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Passo 2<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">0,5 mg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Semanas 5\u20138<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Passo 3<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">1,0\u20131,7 mg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Semanas 9\u201316<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Manuten\u00e7\u00e3o<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">2,4 mg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Semana 17+<\/td>\n<\/tr>\n<\/table>\n<\/figure>\n<h2>Cagrilintida vs medicamentos GLP-1<\/h2>\n<figure class=\"wp-block-table\">\n<table style=\"border-collapse:collapse;width:100%\">\n<tr>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Caracter\u00edstica<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Cagrilintida \/ CagriSema<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Semaglutida<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Tirzepatida<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Mecanismo<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Amilina (+ GLP-1 no CagriSema)<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Apenas GLP-1<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">GLP-1 + GIP<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Estatuto FDA<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Experimental (em an\u00e1lise)<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Aprovada<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Aprovada<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Dose-alvo<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">2,4 mg\/semana<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">2,4 mg\/semana<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">15 mg\/semana<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Perda de peso m\u00e1x. (ensaio)<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">20,4 % CagriSema, 10,8 % isolada<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">15\u201317 % \u00e0s 68 sem.<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">22,5 % \u00e0s 72 sem.<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Semivida<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">7\u20138 dias<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">7 dias<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">5 dias<\/td>\n<\/tr>\n<\/table>\n<\/figure>\n<h2>Reconstitui\u00e7\u00e3o e dosagem (com os 3 mL fornecidos)<\/h2>\n<p>Cada frasco da Clean Peptides vem com 3 mL de \u00e1gua bacteriost\u00e1tica (\u00e1lcool benz\u00edlico 0,9 %). Todos os valores abaixo pressup\u00f5em a reconstitui\u00e7\u00e3o com os 3 mL completos. Numa seringa de insulina U-100 padr\u00e3o, 100 unidades = 1 mL.<\/p>\n<p><strong>F\u00f3rmula r\u00e1pida:<\/strong> concentra\u00e7\u00e3o = pot\u00eancia do frasco \u00f7 3 mL; unidades a extrair = dose (mg) \u00d7 300 \u00f7 pot\u00eancia do frasco (mg).<\/p>\n<figure class=\"wp-block-table\">\n<table style=\"border-collapse:collapse;width:100%\">\n<tr>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Frasco (Clean Peptides)<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Concentra\u00e7\u00e3o<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">0,6 mg<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">1,2 mg<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">2,4 mg<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">5 mg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">1,67 mg\/mL<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">36 u<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">72 u<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">144 u<\/td>\n<\/tr>\n<\/table>\n<\/figure>\n<p>Guarde o produto reconstitu\u00eddo no frigor\u00edfico (2\u20138 \u00b0C) e utilize-o dentro de 28 a 30 dias.<\/p>\n<h2>Dosagem por objetivo<\/h2>\n<ul>\n<li><strong>Perda de peso m\u00e1xima:<\/strong> CagriSema (2,4 mg + 2,4 mg\/semana): 20,4 % \u00e0s 68 semanas (sem diabetes), 13,7 % (diabetes tipo 2). Aumente ambos os componentes em paralelo ao longo de 16 semanas, dura\u00e7\u00e3o de 68 semanas.<\/li>\n<li><strong>Apenas amilina:<\/strong> cagrilintida isolada (at\u00e9 2,4\u20134,5 mg\/semana): at\u00e9 10,8 % em 26 semanas a 4,5 mg. Progress\u00e3o a partir de 0,3 mg.<\/li>\n<\/ul>\n<p>O CagriSema produziu aproximadamente o dobro da perda de peso da cagrilintida isolada, mas acrescenta um segundo medicamento (semaglutida).<\/p>\n<h2>Guia de inje\u00e7\u00e3o<\/h2>\n<p>Lave as m\u00e3os e prepare o material. Desinfete a tampa do frasco e deixe secar. Extraia a sua dose e expulse as bolhas. Escolha o local \u2014 baixo abd\u00f3men (2\u20133 cm do umbigo), parte superior da coxa ou parte de tr\u00e1s do bra\u00e7o. Limpe o local e deixe secar. Injete por via subcut\u00e2nea numa prega beliscada a 45\u00b0. Elimine num contentor de agulhas. Uma vez por semana, no mesmo dia, alternando os locais.<\/p>\n<h2>Dura\u00e7\u00e3o do tratamento<\/h2>\n<figure class=\"wp-block-table\">\n<table style=\"border-collapse:collapse;width:100%\">\n<tr>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Fase<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Semanas<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Descri\u00e7\u00e3o<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Titula\u00e7\u00e3o<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Semanas 1\u201316<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Aumento gradual at\u00e9 2,4 mg, prioridade \u00e0 toler\u00e2ncia digestiva<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Perda de peso ativa<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Semanas 16\u201368<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Dose completa, aqui ocorre a maior parte da perda de peso<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Manuten\u00e7\u00e3o<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Semana 68+<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Estabiliza\u00e7\u00e3o, dados a longo prazo ainda em recolha<\/td>\n<\/tr>\n<\/table>\n<\/figure>\n<p>A interrup\u00e7\u00e3o conduz normalmente a uma recupera\u00e7\u00e3o de peso significativa \u2014 planeie um uso a longo prazo se o objetivo for a manuten\u00e7\u00e3o.<\/p>\n<h2>CagriSema e combina\u00e7\u00f5es<\/h2>\n<p>O CagriSema combina a cagrilintida (an\u00e1logo da amilina) e a semaglutida 2,4 mg (agonista do GLP-1) numa \u00fanica inje\u00e7\u00e3o semanal, unindo dois mecanismos complementares de controlo do apetite para uma perda de peso de cerca do dobro de cada componente isolado.<\/p>\n<h2>Seguran\u00e7a, efeitos secund\u00e1rios e contraindica\u00e7\u00f5es<\/h2>\n<p>Medicamento experimental \u2014 os efeitos a longo prazo e raros ainda est\u00e3o a ser caracterizados. Gastrointestinais (os mais frequentes): n\u00e1useas (pico durante a titula\u00e7\u00e3o), v\u00f3mitos (mais prov\u00e1veis se a titula\u00e7\u00e3o for apressada), diarreia, obstipa\u00e7\u00e3o, diminui\u00e7\u00e3o do apetite. Geralmente ligeiros a moderados e transit\u00f3rios.<\/p>\n<p><strong>Cora\u00e7\u00e3o e tens\u00e3o arterial:<\/strong> a cagrilintida 4,5 mg n\u00e3o provocou prolongamento clinicamente relevante do QT; o CagriSema reduziu a tens\u00e3o arterial no REDEFINE 1 (vigiar se tomar anti-hipertensores).<\/p>\n<p><strong>Contraindica\u00e7\u00f5es esperadas:<\/strong> antecedentes de pancreatite; doen\u00e7a da ves\u00edcula biliar; gravidez\/amamenta\u00e7\u00e3o; diabetes tipo 1. A combina\u00e7\u00e3o CagriSema acrescenta o aviso de classe GLP-1 da semaglutida (cancro medular da tiroide \/ antecedentes de NEM2).<\/p>\n<p><strong>An\u00e1lises de refer\u00eancia:<\/strong> glicose em jejum e HbA1c; painel metab\u00f3lico completo com fun\u00e7\u00e3o hep\u00e1tica; perfil lip\u00eddico; lipase e amilase; frequ\u00eancia card\u00edaca em repouso e tens\u00e3o arterial.<\/p>\n<h2>Erros frequentes<\/h2>\n<ul>\n<li>Come\u00e7ar com a dose-alvo completa sem titular.<\/li>\n<li>Assumir que a monoterapia d\u00e1 resultados de n\u00edvel CagriSema (~10 % vs ~20 %).<\/li>\n<li>Tratar a cagrilintida como um medicamento GLP-1 (\u00e9 um an\u00e1logo da amilina).<\/li>\n<li>Esquecer que o CagriSema cont\u00e9m dois medicamentos.<\/li>\n<li>Esperar dados de seguran\u00e7a de medicamento aprovado.<\/li>\n<li>Erros de reconstitui\u00e7\u00e3o \/ c\u00e1lculo de dose em doses pequenas.<\/li>\n<\/ul>\n<h2>Pontos-chave<\/h2>\n<ul>\n<li>An\u00e1logo da amilina de a\u00e7\u00e3o prolongada \u2014 um mecanismo diferente dos medicamentos GLP-1.<\/li>\n<li>CagriSema (cagrilintida 2,4 mg + semaglutida 2,4 mg) produziu ~20,4 % de perda de peso \u00e0s 68 semanas.<\/li>\n<li>Cagrilintida isolada: at\u00e9 10,8 % em 26 semanas, superando a liraglutida 3,0 mg.<\/li>\n<li>SC uma vez por semana, semivida ~7\u20138 dias; titula\u00e7\u00e3o obrigat\u00f3ria.<\/li>\n<li>N\u00c3O aprovada pela FDA \u2014 CagriSema em an\u00e1lise pela FDA (decis\u00e3o prevista para 2026 segundo informa\u00e7\u00e3o p\u00fablica).<\/li>\n<\/ul>\n<h2>Descarga e recursos relacionados<\/h2>\n<p><a href=\"https:\/\/cleanpeptides.eu\/wp-content\/uploads\/2026\/07\/14-Cagrilintide-Dosage-Guide-Clean-Peptides.pdf\">\ud83d\udcc4 Descarregar o guia PDF completo<\/a><\/p>\n<p><a href=\"https:\/\/cleanpeptides.eu\/product\/cagrilintide-5-mg\/\">Cagrilintida 5 mg<\/a> \u00b7 <a href=\"https:\/\/cleanpeptides.eu\/retatrutide-dosage-guide\/\">Guia de dosagem Retatrutida<\/a><\/p>\n<h2>Refer\u00eancias<\/h2>\n<ol>\n<li>Garvey WT, et al. \u00abCoadministered Cagrilintide and Semaglutide in Overweight or Obesity.\u00bb N Engl J Med. 2025;393(7):635-647.<\/li>\n<li>Davies MJ, et al. \u00abCagrilintide-Semaglutide in Overweight\/Obesity and Type 2 Diabetes.\u00bb N Engl J Med. 2025;393(7):648-659.<\/li>\n<li>Lau DCW, et al. \u00abOnce-weekly cagrilintide for weight management: a Phase 2 trial.\u00bb Lancet. 2021;398(10317):2172.<\/li>\n<li>Enebo LB, et al. \u00abCagrilintide with semaglutide 2.4 mg: a Phase 1b trial.\u00bb Lancet. 2021;397(10286):1736-1748.<\/li>\n<li>Gabe MBN, et al. \u00abCagrilintide and QTc: a thorough QT study.\u00bb Diabetes Obes Metab. 2024;26(12):5805-5811.<\/li>\n<\/ol>\n\n    <div class=\"xs_social_share_widget xs_share_url after_content \t\tmain_content  wslu-style-1 wslu-share-box-shaped wslu-fill-colored wslu-none wslu-share-horizontal wslu-theme-font-no wslu-main_content\">\n\n\t\t\n        <ul>\n\t\t\t        <\/ul>\n    <\/div> \n","protected":false},"excerpt":{"rendered":"<p>Apenas para fins de investiga\u00e7\u00e3o \u2014 n\u00e3o destinado ao uso humano. A Clean Peptides n\u00e3o fornece aconselhamento sobre dosagem ou [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"class_list":["post-10272","page","type-page","status-publish","hentry"],"_hostinger_reach_plugin_has_subscription_block":false,"_hostinger_reach_plugin_is_elementor":false,"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/cleanpeptides.eu\/pt-pt\/wp-json\/wp\/v2\/pages\/10272","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cleanpeptides.eu\/pt-pt\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/cleanpeptides.eu\/pt-pt\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/cleanpeptides.eu\/pt-pt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cleanpeptides.eu\/pt-pt\/wp-json\/wp\/v2\/comments?post=10272"}],"version-history":[{"count":0,"href":"https:\/\/cleanpeptides.eu\/pt-pt\/wp-json\/wp\/v2\/pages\/10272\/revisions"}],"wp:attachment":[{"href":"https:\/\/cleanpeptides.eu\/pt-pt\/wp-json\/wp\/v2\/media?parent=10272"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}